Qiagen NV (NASDAQ:QGEN)‘s stock had its “buy” rating reissued by stock analysts at DZ Bank AG in a report released on Monday.

QGEN has been the topic of a number of other reports. Zacks Investment Research cut Qiagen NV from a “hold” rating to a “sell” rating in a research report on Tuesday, June 21st. Piper Jaffray Cos. reissued a “hold” rating on shares of Qiagen NV in a report on Thursday, May 26th. Commerzbank AG reissued a “buy” rating on shares of Qiagen NV in a report on Wednesday, August 31st. Deutsche Bank AG reissued a “buy” rating on shares of Qiagen NV in a report on Monday, June 6th. Finally, Jefferies Group reissued a “hold” rating on shares of Qiagen NV in a report on Thursday, August 4th. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $25.36.

Analyst Recommendations for Qiagen NV (NASDAQ:QGEN)

Qiagen NV (NASDAQ:QGEN) opened at 26.19 on Monday. The firm’s 50-day moving average is $26.76 and its 200-day moving average is $23.35. Qiagen NV has a 12 month low of $19.94 and a 12 month high of $28.04. The company has a market capitalization of $6.13 billion, a PE ratio of 52.38 and a beta of 0.90.

Qiagen NV (NASDAQ:QGEN) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.24 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.01. Qiagen NV had a return on equity of 9.21% and a net margin of 9.13%. The firm had revenue of $334.40 million for the quarter, compared to analysts’ expectations of $326.73 million. During the same period in the previous year, the firm earned $0.26 EPS. The business’s quarterly revenue was up 4.7% on a year-over-year basis. Equities analysts anticipate that Qiagen NV will post $1.09 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in QGEN. Douglas Lane & Associates LLC bought a new position in Qiagen NV during the first quarter valued at $42,915,000. Manning & Napier Advisors LLC boosted its position in Qiagen NV by 31.7% in the second quarter. Manning & Napier Advisors LLC now owns 6,111,364 shares of the company’s stock worth $133,287,000 after buying an additional 1,470,315 shares during the last quarter. Citadel Advisors LLC acquired a new position in Qiagen NV during the second quarter worth about $28,145,000. Harris Associates L P boosted its position in Qiagen NV by 62.6% in the second quarter. Harris Associates L P now owns 3,331,940 shares of the company’s stock worth $72,670,000 after buying an additional 1,282,240 shares during the last quarter. Finally, Exane Asset Management acquired a new position in Qiagen NV during the second quarter worth about $14,260,000. 58.76% of the stock is currently owned by hedge funds and other institutional investors.

About Qiagen NV

QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.

5 Day Chart for NASDAQ:QGEN

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with Analyst Ratings Network's FREE daily email newsletter.